# Uptravi (selexipag) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/selexipag

> The FDA approved Uptravi (selexipag), sponsored by JOHNSON & JOHNSON (JNJ), on July 29, 2021.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Uptravi (selexipag) |
| Codes |  |
| Sponsor | JOHNSON & JOHNSON (JNJ) https://sec-api.dev/companies/jnj/catalysts |
| Indications | pah, such |
| Modality |  |
| FDA designations | priority review |

## Timeline

### January 30, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA207947 SUPPL-8 (Efficacy): submission_status AP, submission_status_date 20210130, review_priority STANDARD; sponsor_name ACTELION; product UPTRAVI (SELEXIPAG)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA207947%22

### July 29, 2021: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA214275 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20210729, review_priority STANDARD; sponsor_name ACTELION; product UPTRAVI (SELEXIPAG)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214275%22

### Mar 2026: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 3. Indication: PAH, such.
- First seen 2026-05-11, last confirmed 2026-11-10.
- SEC Form 10-Q (accession 0001104659-26-124752): "IP-agonists to treat PAH, such as the oral formulations of selexipag, marketed by Actelion, and ralinepag, being developed by UTC, who announced positive top-line Phase 3 results in March 2026." https://www.sec.gov/Archives/edgar/data/1819576/000110465926124752/lqda-20260930x10q.htm
- SEC Form 10-Q (accession 0001104659-26-094410): "IP-agonists to treat PAH, such as the oral formulations of selexipag, marketed by Actelion, and ralinepag, being developed by United Therapeutics, who announced positive top-line Phase 3 results in March 2026 and intends to submit for FDA approval later this year." https://www.sec.gov/Archives/edgar/data/1819576/000110465926094410/lqda-20260630x10q.htm
- SEC Form 10-Q (accession 0001104659-26-058252): "IP-agonists to treat PAH, such as the oral formulations of selexipag, marketed by Actelion, and ralinepag, being developed by United Therapeutics, who announced positive top-line Phase 3 results in March 2026 and intends to submit for FDA approval later this year." https://www.sec.gov/Archives/edgar/data/1819576/000110465926058252/lqda-20260331x10q.htm

### May 23, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA207947 SUPPL-14 (Efficacy): submission_status AP, submission_status_date 20260523, review_priority PRIORITY; sponsor_name ACTELION; product UPTRAVI (SELEXIPAG)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA207947%22

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/selexipag.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Uptravi (selexipag) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/selexipag

```bibtex
@misc{secapidev_pdufa_selexipag_20261116,
  title        = {Uptravi (selexipag) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/selexipag}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_selexipag_20261116","title":"Uptravi (selexipag) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/selexipag","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
